Gilead Sciences GmbH

Fraunhoferstr. 17
82152 Planegg


Contact WebSite

Article

Gilead and Compugen Strike Exclusive Deal for New Immunotherapy Program
22.12.2023 • News

Gilead and Compugen Strike Exclusive Deal for New Immunotherapy Program

Gilead has exclusive rights for the advancement and commercialization of anti-IL18 binding protein antibodies targeting various tumor types. Gilead commits to a significant deal, including a €55 million ($60 million) upfront payment and a €27 million ($30 million) milestone payment in the near term, with a total potential value of up to €775 million ($848 million).

Gilead Buys Oxford Spin-out MiroBio
10.08.2022 • News

Gilead Buys Oxford Spin-out MiroBio

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.